


CLAIMS:

1. A compound of general formula (I),



any of its enantiomers or any mixture of its enantiomers, or a pharmaceutically acceptable salt thereof,

wherein

Q is $-\text{CH}_2-\text{CH}_2-$ or $-\text{CH}_2-\text{CH}_2-\text{CH}_2-$;

one of R^1 and R^2 is $-\text{CH}_2-\text{CH}_2-\text{CH}_2-\text{R}^3$, $-\text{CH}_2-\text{CH}=\text{CH}-\text{R}^3$, or $-\text{CH}_2-\text{C}\equiv\text{C}-\text{R}^3$;

wherein R^3 is aryl or heteroaryl;

which aryl and heteroaryl is optionally substituted with one or more substituents selected from the group consisting of:

halogen, hydroxy, amino, cyano, nitro, trifluoromethyl, alkoxy,

cycloalkoxy, alkyl, cycloalkyl, cycloalkylalkyl, alkenyl, and alkynyl; and

the other of R^1 and R^2 is $-\text{CO}-\text{R}^4$;

wherein R^4 is alkyl, cycloalkyl, cycloalkylalkyl, aryl, or arylalkyl.

2. The compound according to claim 1, wherein

Q is $-\text{CH}_2-\text{CH}_2-$.

3. The compound according to claim 1, wherein

Q is $-\text{CH}_2-\text{CH}_2-\text{CH}_2-$.

4. The compound according to any one of claims 1-3, wherein

one of R^1 and R^2 is $-\text{CH}_2-\text{CH}=\text{CH}-\text{R}^3$;

wherein R^3 is defined as in claim 1.

5. The compound according to any one of claims 1-4, wherein R^4 is alkyl.

6. The compound according to claim 1, wherein

Q is $-\text{CH}_2-\text{CH}_2-$ or $-\text{CH}_2-\text{CH}_2-\text{CH}_2-$;

one of R^1 and R^2 is $-\text{CH}_2-\text{CH}=\text{CH}-\text{R}^3$, or $-\text{CH}_2-\text{C}\equiv\text{C}-\text{R}^3$;

wherein R^3 is phenyl; and

the other of R¹ and R² is -CO-R⁴;
wherein R⁴ is alkyl.

7. A compound of claim 1 which is
5 (±)-1-[9-(3-Phenyl-allyl)-3,9-diaza-bicyclo[4.2.1]non-3-yl]-propan-1-one;
(±)-1-[10-(3-Phenyl-allyl)-3,10-diaza-bicyclo[4.3.1]dec-3-yl]-propan-1-one;
(±)-1-[3-(3-Phenyl-allyl)-3,9-diazabicyclo[4.2.1]non-9-yl]-propan-1-one;
or any of its enantiomers or any mixture of its enantiomers, or a pharmaceutically
acceptable salt thereof.
8. A pharmaceutical composition, comprising a therapeutically effective amount of a
10 compound of any one of claims 1-7, or any of its enantiomers or any mixture of
its enantiomers, or a pharmaceutically acceptable salt thereof, together with at
least one pharmaceutically acceptable carrier, excipient or diluent.
9. The use of a compound according to any one of claims 1-7, or any of its
15 enantiomers or any mixture of its enantiomers, or a pharmaceutically acceptable
salt thereof, for the manufacture of a pharmaceutical composition for the
treatment, prevention or alleviation of a disease or a disorder or a condition of a
mammal, including a human, which disease, disorder or condition is responsive
to modulation of the opioid receptor.
20
10. The use according to claim 9, wherein the disease, disorder or condition
responsive to modulation of the opioid receptor is pain, postoperative pain,
chronic pain, cancer pain, neuropathic pain, pain during labour and delivery, drug
addiction, heroin addiction, cocaine addiction, alcoholism, irritable bowel
25 syndrome, constipation, nausea, vomiting, pruritic dermatoses, allergic
dermatitis, atopy, eating disorders, opiate overdoses, depression, smoking,
sexual dysfunction, shock, stroke, spinal damage, or head trauma.
11. A method for treatment, prevention or alleviation of a disease or a disorder or a
30 condition of a living animal body, including a human, which disorder, disease or
condition is responsive to modulation of the opioid receptor, which
method comprises the step of administering to such a living animal body in need
thereof a therapeutically effective amount of a compound according to any one of
the claims 1-7, or any of its enantiomers or any mixture of its enantiomers, or a
35 pharmaceutically acceptable salt thereof.